dissemin
use
sensit
molecular
method
viral
detect
opportun
evalu
role
respiratori
virus
acut
chronic
respiratori
ill
expand
past
decad
acut
wheez
ill
common
especi
young
children
viral
agent
shown
found
episod
use
sensit
detect
method
multipl
disclosur
author
conflict
report
keyword
human
metapneumoviru
bocaviru
influenza
viru
wheez
asthma
respiratori
virus
rhinoviru
respiratori
syncyti
viru
associ
acut
wheez
ill
contribut
recurrentwheez
well
studi
children
human
metapneumoviru
lower
respiratori
tract
infect
may
increas
risk
subsequ
recurr
wheez
sever
year
initi
infect
virus
associ
acut
wheez
ill
includ
rhinoviru
rv
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
influenza
viru
parainfluenza
viru
adenoviru
human
bocaviru
hbov
coronaviru
enteroviru
tabl
virus
also
shown
associ
asthma
exacerb
rv
rsv
frequent
detect
pathogen
see
tabl
rsv
preval
younger
children
winter
month
rv
preval
older
children
larg
bodi
evid
implic
associ
rv
rsv
subsequ
develop
recurr
wheez
andor
asthma
virus
rv
rsv
detect
wheez
ill
limit
data
regard
associ
virus
asthma
conduct
studi
evalu
longterm
consequ
virus
challeng
sever
reason
first
detect
rate
virus
often
lower
compar
rv
rsv
much
larger
cohort
requir
perform
studi
adequ
represent
patient
infect
virus
prospect
studi
investig
role
hmpv
infect
develop
wheez
asthma
requir
screen
children
infect
hmpv
period
recruit
second
establish
appropri
anim
model
challeng
exist
model
may
adequ
model
human
infect
evalu
longterm
outcom
third
difficult
teas
specif
contribut
virus
associ
rv
rsv
confound
analysi
given
high
rate
coinfect
virus
instanc
commun
cohort
children
high
atop
risk
wheezi
febril
lower
respiratori
tract
infect
lrti
first
year
life
associ
higher
risk
persist
wheez
odd
ratio
asthma
age
year
atop
age
year
respiratori
viru
detect
patient
febril
lrti
larg
proport
detect
virus
rv
rsv
observ
associ
may
primarili
caus
effect
rv
rsv
infect
howev
data
suggest
viral
infect
earli
life
caus
may
import
increas
risk
asthma
highrisk
birth
cohort
studi
demark
number
respiratori
episod
first
year
life
associ
develop
asthma
age
year
regardless
viru
type
articl
focus
virus
hmpv
hbov
influenza
viru
associ
wheez
ill
studi
provid
aggreg
avail
data
review
current
research
investig
role
virus
acut
chronic
respiratori
diseas
hmpv
paramyxoviru
first
discov
van
den
hoogen
colleagu
similar
rsv
hmpv
singlestrand
rna
viru
belong
pneumovirida
subfamili
caus
mani
symptom
rsv
typic
symptom
hmpv
infect
includ
mild
selflimit
acut
upper
respiratori
tract
infect
sever
lrti
wheez
pneumonia
frequent
caus
bronchiol
young
children
cough
rhinorrhea
wheez
fever
commonli
report
symptom
children
infect
hmpv
virtual
children
evid
exposur
hmpv
age
year
hmpv
respons
signific
portion
respiratori
tract
infect
associ
larg
burden
hospit
outpati
visit
younger
children
tend
peak
late
winter
spring
season
typic
decemb
april
often
peak
februari
march
compar
infect
virus
conflict
data
whether
hmpv
infect
result
greater
hypoxemia
durat
hospit
intens
care
unit
icu
stay
sever
ill
wors
histori
extrem
prematur
although
hmpv
caus
wheez
lower
respiratori
tract
symptom
contribut
hmpv
asthma
exacerb
vari
among
differ
popul
asthma
exacerb
detect
rate
hmpv
approxim
worldwid
wherea
hmpv
lrti
much
higher
proport
diagnosi
asthma
studi
children
hmpv
lrti
unit
state
carri
diagnosi
asthma
histori
wheez
studi
children
hmpv
spain
infect
hmpv
alon
carri
diagnosi
recurr
wheez
asthma
higher
rate
rsv
adenoviru
similar
rv
hbov
children
rsv
like
diagnosi
bronchiol
children
hmpv
hmpv
caus
ill
consist
bronchiol
children
may
diagnos
less
often
term
given
often
synonym
rsv
infect
young
children
nonetheless
hmpv
caus
wheez
young
children
often
precipit
episod
wheez
prone
asthmat
import
caus
viralinduc
asthma
exacerb
children
asthma
studi
shown
synergist
effect
allerg
characterist
host
ie
immunoglobulin
e
level
hous
dust
sensit
sever
asthma
exacerb
rv
interact
allergi
host
hmpv
infect
well
studi
contrast
larg
number
studi
report
associ
hmpv
earli
childhood
acut
wheez
ill
asthma
time
ill
spars
data
longterm
consequ
acut
infect
one
studi
garciagarcia
colleagu
retrospect
identifi
children
year
age
hospit
hmpv
rsv
bronchiol
first
month
life
contact
assess
diagnosi
asthma
time
studi
children
hmpvposit
bronchiol
without
coinfect
cours
prior
year
octob
june
abl
obtain
followup
children
prior
histori
wheez
select
random
sampl
children
time
period
rsv
bronchiol
obtain
followup
children
diagnosi
recurr
wheez
asthma
frequent
children
histori
hmpv
bronchiol
rsv
bronchiol
compar
control
children
hospit
around
time
rotaviru
hmpv
bronchiol
strongest
independ
risk
factor
asthma
confid
interv
ci
follow
rsv
bronchiol
ci
allerg
rhiniti
ci
age
year
anoth
studi
prospect
follow
prematur
infant
viral
lrti
although
track
wheez
asthma
statu
found
airway
resist
measur
increas
year
age
although
studi
includ
infant
hmpv
stronger
evid
longterm
effect
hmpv
ltri
found
recent
prospect
studi
evalu
effect
hmpv
infect
wheez
asthma
outcom
children
less
year
age
hospit
treat
emerg
room
hmpv
lrti
prior
histori
wheez
prospect
follow
along
control
group
outcom
assess
everi
month
year
final
followup
late
year
prospect
studi
design
enabl
investig
obtain
child
wheez
histori
captur
outcom
secur
longitudin
fashion
followup
data
collect
children
hpmv
lrti
control
children
hmpv
lrti
higher
likelihood
wheez
episod
followup
period
hazard
ratio
hr
ci
control
addit
children
hmpv
lrti
earlier
onset
recurr
wheez
without
cold
control
children
fig
associ
develop
asthma
statist
signific
hr
ci
p
although
number
children
diagnos
asthma
larger
hmpv
group
control
group
learn
studi
suggest
increas
risk
asthma
develop
follow
hmpv
infect
earli
life
mechan
shortterm
longterm
patholog
effect
hmpv
infect
well
studi
compar
rsv
infect
hmpv
mice
shown
lead
persist
viral
rna
pulmonari
inflamm
airway
hyperrespons
sever
month
infect
suggest
longterm
patholog
chang
occur
hmpv
infect
studi
mice
human
suggest
sever
differ
molecular
mechan
hmpv
affect
airway
inflamm
function
time
acut
infect
often
compar
mechan
viral
caus
alveolar
macrophag
activ
may
augment
hmpv
infect
lead
detriment
effect
airway
wherea
alveolar
macrophag
deplet
seen
rsv
may
provid
protect
harm
effect
viru
chemokin
profil
nasal
secret
also
shown
differ
hmpv
high
concentr
interleukin
il
neutrophil
chemotact
factor
low
concentr
rant
regul
activ
normal
tcell
express
secret
eosinophil
chemotact
factor
individu
infect
hmpv
compar
increas
rant
concentr
seen
rsv
anoth
studi
children
year
age
hmpv
infect
differ
measur
cellmedi
immun
distinguish
hmpv
respiratori
virus
rsv
influenza
thymic
stromal
lymphopoietin
tslp
well
plasma
level
higher
children
wheez
hmpv
without
wheez
hmpv
without
wheez
anoth
respiratori
viru
tslp
implic
mediat
pathway
pediatr
asthma
higher
plasma
tslp
level
correl
poor
asthma
control
tslp
promot
basophil
product
type
inflamm
infect
human
airway
epitheli
cell
hmpv
induc
express
tslp
well
lead
upregul
wherea
tslp
blockad
led
reduc
lung
inflamm
indic
activ
tslp
pathway
initi
airway
inflamm
hmpv
acut
infect
studi
may
suggest
involv
tslp
pathway
molecular
mechan
hmpv
lead
recurr
wheez
asthma
phenotyp
although
investig
warrant
hbov
parvoviru
discov
pool
nasopharyng
sampl
molecular
screen
subsequ
studi
shown
hbov
genotyp
commonli
detect
respiratori
sampl
children
acut
wheez
children
acut
wheez
first
time
hbov
detect
howev
also
known
coinfect
rate
hbov
virus
high
addit
detect
asymptomat
individu
also
frequent
hbov
found
present
healthi
control
admit
hospit
elect
surgeri
particip
household
studi
symptom
nasal
sampl
prospect
collect
month
hbov
detect
occur
without
symptom
viral
persist
thought
respons
high
frequenc
coinfect
hbov
implic
import
respiratori
pathogen
mani
precis
patholog
contribut
hbov
acut
respiratori
diseas
still
accur
defin
hbov
may
passeng
caus
pathogen
hbov
may
interfer
rvinduc
immun
respons
acut
wheez
lukkarinen
colleagu
compar
thelper
th
proinflammatori
cytokin
respons
profil
young
children
rv
hbov
rvhbov
coinfect
acut
wheez
ill
unlik
rv
hbov
infect
associ
system
proinflammatori
respons
rvhbov
coinfect
result
immun
respons
although
bocaviru
frequent
detect
seem
associ
acut
wheez
episod
data
longterm
consequ
acut
infect
spars
one
retrospect
studi
spain
identifi
children
previous
hospit
hbov
n
rsv
bronchiol
n
first
month
life
evalu
assess
clinic
outcom
includ
diagnosi
asthma
presenc
atopi
age
year
children
hbov
group
develop
recurr
wheez
fifti
percent
hbov
group
rsv
group
diagnosi
asthma
age
year
proport
atopi
similar
among
hbov
rsv
anoth
studi
children
hospit
acut
viral
wheez
show
children
hbovassoci
bronchiol
recurr
wheez
year
initi
hospit
less
often
children
rvassoci
bronchiol
hbov
vs
rv
associ
hbov
lrti
earli
life
asthma
inconclus
larger
prospect
studi
requir
confirm
find
influenza
virus
respons
averag
million
annual
hospit
day
million
outpati
visit
one
frequent
detect
virus
asthma
exacerb
long
identifi
precipit
asthma
exacerb
age
group
peopl
asthma
exacerb
detect
rate
influenza
viru
approxim
worldwid
flu
season
preval
influenza
virus
high
wheez
infant
adult
acut
asthma
exacerb
although
involv
influenza
viru
common
asthma
exacerb
influenza
viru
infrequ
caus
acut
wheez
ill
younger
children
author
awar
studi
evalu
role
influenza
viru
lrti
develop
recurr
wheez
andor
asthma
later
life
cytokin
implic
import
driver
influenzainduc
asthma
exacerb
anim
studi
influenzainfect
mous
model
express
upregul
shift
balanc
immun
recent
studi
shown
produc
ciliat
bronchial
cell
type
ii
alveolar
cell
viralinduc
exacerb
human
mice
dampen
innat
adapt
cytotox
respons
subsequ
result
increas
viral
load
enhanc
airway
inflamm
underli
influenzainduc
asthma
exacerb
meanwhil
heighten
product
induc
substanti
product
type
innat
lymphoid
cell
cytokineproduc
cell
promot
allerg
inflamm
mous
model
asthma
atop
dermat
anoth
studi
influenza
infect
induc
acut
airway
hyperreact
medic
suggest
import
axi
influenzainduc
acut
asthma
exacerb
whether
asthmat
frequent
infect
influenza
viru
still
matter
debat
shown
patient
asthma
reduc
type
interferon
ifn
respons
rv
infect
studi
confirm
observ
human
bronchial
epitheli
cell
patient
asthma
show
increas
ifnlambda
level
preserv
ifnbeta
level
infect
influenza
viru
although
viral
level
higher
asthmat
compar
nonasthmat
us
studi
children
asthma
found
infect
twice
often
nonasthmat
influenza
monitor
weekli
nasal
sampl
symptom
score
season
regardless
accept
asthma
risk
factor
sever
diseas
influenza
acquir
patient
asthma
list
prioriti
popul
vaccin
popul
studi
pandem
provid
interest
observ
regard
suscept
asthma
found
risk
factor
hospit
found
hospit
patient
worldwid
nonetheless
observ
also
made
asthma
may
protect
patient
hospit
influenza
patient
asthma
decreas
risk
icu
stay
mechan
ventil
death
compar
chronic
condit
cardiovascular
diseas
obes
observ
protect
effect
may
part
explain
earli
hospit
admiss
andor
favor
respons
steroid
mous
model
protect
effect
allerg
asthma
influenza
infect
recapitul
increas
eosinophil
level
asthmat
airway
may
one
mechan
put
antigenpres
function
eosinophil
enhanc
influenzaspecif
cell
infect
mediat
viral
clearanc
influenza
viru
mous
asthma
model
rapid
induct
type
iii
ifn
natur
killer
cell
tgfbeta
also
observ
asthmat
mice
influenza
infect
indic
potenti
mechan
enhanc
antivir
immun
influenza
asthmat
influenza
vaccin
recommend
patient
asthma
mani
countri
clear
evid
show
protect
benefit
recent
cochran
review
includ
trial
across
world
conclud
inactiv
influenza
vaccin
provid
signific
reduct
number
durat
influenzarel
asthma
exacerb
safeti
concern
rais
earlier
studi
show
decreas
peak
flow
follow
administr
inactiv
influenza
vaccin
subsequ
studi
netherland
larg
studi
unit
state
enrol
patient
asthma
confirm
increas
risk
advers
event
includ
asthma
exacerb
within
week
follow
inject
cochran
review
also
conduct
systemat
review
trial
compar
intranas
vaccin
intramuscular
infect
infant
older
children
conclud
event
rate
asthma
exacerb
wheez
similar
vaccin
type
recent
studi
unit
kingdom
evalu
safeti
intranas
live
attenu
influenza
vaccin
atop
children
welldefin
allergi
egg
sixtyseven
percent
children
asthma
addit
egg
allergi
system
reaction
follow
inject
mild
selflimit
symptom
dose
given
children
also
ensur
safeti
respiratori
virus
rv
rsv
especi
hmpv
influenza
viru
hbov
detect
frequent
acut
wheez
ill
interact
virus
allerg
host
contribut
develop
asthma
acut
infect
well
understood
although
evid
suggest
children
hmpv
lrti
higher
likelihood
subsequ
recurr
wheez
sever
year
initi
infect
